This medication conflict checker helps IgA nephropathy patients find out if their current medications could affect clinical trial eligibility. Select one or more medications below to instantly screen active trials for potential conflicts.
IgAN treatment has changed dramatically in the past few years. Where patients used to rely mainly on blood pressure medications and immunosuppressants, there are now multiple FDA-approved therapies that target the specific mechanisms driving the disease: complement inhibitors, APRIL/BAFF pathway blockers, endothelin receptor antagonists, and targeted-release budesonide. Many patients are on a combination of these newer drugs plus standard RAAS blockade and SGLT2 inhibitors. Each clinical trial has its own rules about which medications you can continue and which ones require a washout period.
Endothelin Receptor Antagonists
Filspari (sparsentan), Vanrafia (atrasentan) — sparsentan is a dual endothelin/angiotensin blocker that replaces your ACE inhibitor or ARB. Atrasentan is a selective endothelin A blocker. Trials testing other IgAN mechanisms may exclude patients on these drugs or require a washout. Since sparsentan already blocks angiotensin receptors, patients taking it typically stop their separate ACE inhibitor or ARB.
Complement & APRIL/BAFF Inhibitors
Fabhalta (iptacopan), Voyxact (sibeprenlimab), Trutakna (atacicept) — these newer targeted therapies are the most actively studied drugs in IgAN trials right now. Trials comparing one mechanism to another will often exclude patients already on a competing targeted therapy. Iptacopan blocks complement factor B, while sibeprenlimab and atacicept target the APRIL/BAFF pathway that drives abnormal IgA production.
TARPEYO & Immunosuppressants
TARPEYO (targeted budesonide), prednisone, CellCept, Imuran, Rituxan, cyclosporine — targeted-release budesonide is IgAN-specific and may be required to wash out for 2-3 months. Systemic immunosuppressants like prednisone, mycophenolate, and rituximab are commonly excluded in trials, often with washout periods of 3 to 12 months depending on the drug.
Foundation Therapy (RAAS + SGLT2)
ACE inhibitors, ARBs, Farxiga, Jardiance — most IgAN trials actually require patients to be on stable, maximally-tolerated RAAS blockade for at least 12 weeks before enrollment. SGLT2 inhibitors are increasingly required as well. These foundation therapies are rarely the reason you'd be excluded from a trial.
Most trials require you to already be on RAAS blockade
Unlike many other diseases where medications get you excluded, IgAN trials typically require a stable dose of an ACE inhibitor or ARB (at the highest dose you can tolerate) for at least 12 weeks before screening. If you're not already on one, you may need to start before you can qualify. If the checker flags your ACE inhibitor or ARB, look at the excerpt carefully because it's more likely about dose stability requirements than an outright exclusion.
Sparsentan replaces your ACE inhibitor or ARB
Sparsentan (Filspari) blocks both endothelin and angiotensin II receptors, so it serves as your RAAS blocker. If you're on sparsentan, you should not also be taking a separate ACE inhibitor or ARB. Some trials that require stable RAAS blockade may accept sparsentan as fulfilling that requirement, while others may specifically exclude it. The checker will flag which trials mention sparsentan or endothelin antagonists in their criteria.
Your kidney function (eGFR) matters as much as your medications
Most IgAN trials require an eGFR of at least 30 mL/min, and many set the floor at 20 or 25. They also typically require proteinuria above 0.75 to 1 gram per day. Even if your medications don't conflict with a trial, your lab values are a critical part of eligibility. Bring your most recent blood work and urine protein results when you talk to a study team.
Don't see your medication listed?
The checker covers approximately 40 medications across 10 categories most relevant to IgAN patients: disease-specific therapies (sparsentan, iptacopan, sibeprenlimab, TARPEYO, and others), RAAS blockers, SGLT2 inhibitors, immunosuppressants, blood pressure medications, diabetes medications, statins, and CKD-related treatments like ESAs and phosphate binders. If your medication isn't listed, that means we haven't found it commonly mentioned in IgAN trial exclusion criteria. You should still mention all medications to the study team when you contact them.
How the medication conflict checker works: This free tool helps IgA nephropathy patients learn if their current medications could affect clinical trial eligibility. It scans the published eligibility criteria of every active IgAN trial and flags which ones may exclude your specific treatment. Matches are categorized by confidence level: high confidence means the trial names your exact drug, medium confidence means it references your drug class, and low confidence means it uses broad category language that may or may not apply to you. Select one or more of your medications above to instantly see which trials you may still qualify for and which ones could be a problem. Always confirm eligibility directly with the study team, as final decisions involve your complete medical history, kidney biopsy findings, proteinuria levels, eGFR, and your nephrologist's assessment.
Across 1,853 open rare disease treatment trials, a third exclude people over a medication they commonly take. See which medications and diseases, in our September 2026 analysis.
